Liquid biopsy

Liquid biopsy was not always an option for molecular laboratories due to the short 4-hour window from blood collection to cfDNA extraction, time intensive workflows, and the need for specific technical expertise.

From sample collection, polymerase chain reaction (PCR) testing, and next-generation sequencing (NGS)—Roche’s robust liquid biopsy portfolio is bringing new possibilities to clinical research and diagnostics.

From simple PCR workflows to the turnkey NGS kit-based solution, the Roche Liquid Biopsy portfolio facilitates in-house adoption of liquid biopsy testing.

• cfDNA collection
• Tumor profiling
• Surveillance for minimal residual disease - RUO
• Longitudinal monitoring for tumor burden - RUO

• Collection tubes providing a high degree of stability to prevent cell lysis up to 8 hours*
• Reliable PCR assays backed by robust clinical evidence
• Ultra-sensitive NGS ctDNA tumor profiling, surveillance and monitoring assays that are purpose-built for liquid biopsy research
• Sample stability in transit and at different temperatures*
• PCR assays run on the trusted cobas^® platform
• Fully supported by Roche’s leading service, logistics and distribution network

As the intricacies of cancer become better understood, new discoveries will follow.

From uncovering the next major breakthrough to monitoring for disease progression, the Roche liquid biopsy portfolio can help make your vision of personalized patient care a reality.